TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Covid19 -Impact on Compliance and Quality Culture

Covid19 -Impact on Compliance and Quality Culture

So far, 2020 has been a tumultuous year for pharmaceutical manufacturers and distributors and we have no sooner conquered one hurdle or challenge when another one has come our way.  Initially there was a rush to put appropriate remote working and social distancing measures in place, and then as new government guidance was published, companies had to decide how and when they would build on these measures such as the introduction of face masks and temperature monitoring once the initial lockdown was over and then moving to more sophisticated measure(s) such as plexiglass screening to improve segregation.

Aside from these safety concerns, we are also assisting our clients with compliance concerns and issues regarding the practical challenges with the full implementation of the Quality Management Systemin a remote working environment, particularly for companies that do not yet have established electronic systems or remote working access to shared folders or drives.

These issues can manifest themselves as higher deviation rates for items such as process variation, delay in CAPA implementation, changed cleaning regimes and general staff shortages or unavailability due to the Covid19 restrictions.  The concern in the industry is that these issues may lead to inspection observations thus adding to the resource burden.

Additional changes have occurred in the Quality Culture of organisations where Covid19 has necessitated a shift in responsibility for Quality during production onto the production personnel where the requirement for reduced teams of skeleton staff on site has often moved the QA department to remote working. Quality is now truly everyone’s responsibility and although many organisations have experienced positive improvements in teamwork and shared responsibility, the negative compliance impacts also cannot be ignored.

The main hot topics where we have received feedback from clients include:

  • Delays in document approvals and CAPA implementation.
  • Additional Deviations to manage Covid-19 challenges and resource constraints.
  • Difficulty maintaining appropriate levels of Management oversight due to remote working.
  • Issues with Vendor management, access to contract sites and the switch to virtual audits.
  • Data integrity, privacy and GDPR concerns as a result of working from home.
  • Issues with the cleaning, contamination control and testing programs due to Covid-19 resource constraints.
  • The introduction of masks and socially distant work practices in operations.
  • The self-Inspection program and its effectiveness in the challenging revised arrangements.
  • Remote review by QPs

What is needed now?

It is important that Pharmaceutical manufacturers and distributors reflect on several tough questions regarding what has happened at their sites over the past nine months and whether sufficient care has been taken to ensure continued compliance with the QMS and with the regulatory guidelines.  The Covid-19 planning that commenced back in March require constant review as the situation changed and guidance related to changing risks has been ever evolving.  Therefore, It may be useful  to take a look back over the chronology of events and explore Covid-19 risk management planning in light of all the regulatory expectations that were issued to clarify the responsibilities of manufacturers and distributors during the unprecedented environment of the pandemic and to explore  If appropriate measures were taken to not only safeguard public health but also the health of the QMS.

We need to ask if during the Covid19 response and planning, were the risks and the continued compliance with the QMS assessed and were appropriate measures taken to ensure the QMS could continue to operate effectively? In some cases we also need to review how the “new normal” will impact our way of working and what are the steps we need to take to ensure that a move to more remote working is managed in a way that ensures minimal impact on regulatory compliance and product quality.

Also was there a frequent review of the Covid19 plans to ensure they were consistent with the changing situation, guidance from government and the regulatory authority expectations?

 What we at Pharmalex can do to support you:

PharmaLex have subject matter experts with in-depth experience who are happy to support your company with assessing the compliance risks in your organisation that may have arisen due to the pandemic.

This support could include:

  • Providing expert opinion on the state of compliance of the Quality Management System.
  • Providing support with completing Deviation and CAPA actions in your Quality Management System.
  • Maintenance of validation programmes.
  • Reviewing and completion of your vendor audit program by conducting audits on your behalf.

For more information on this or any other services that PharmaLex provide, why not get in touch by connecting with us on +353 1 846 4742 or email us at contact@pharmalex.com.

Related posts
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Virtual Audits: To be, or not to be, that is the question
Virtual Audits: To be, or not to be, that is the question
26th January 2022
Quality Risk Management ICH Q9 – Revision published for public comments
Quality Risk Management ICH Q9 – Revision published for public comments
5th January 2022
Search
Upcoming Events

September 28 - May 29th, 2022

NLS DAYS 2022

Visit us at booth X51

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
20 May

PharmaLex is excited to be supporting the #ARCSannualconference again this year. Be sure to join their sessions and visit our team at stand 44.

Find out more: https://lnkd.in/g6fbC2kr

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • There was a close relationship between the regulatory strategy and the writing activities. You developed a fine-tuned regulatory strategy which will be a key factor to smooth the approval of our dossier.

    Large Pharma, Global
    VP Regulatory Strategy
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for